PANoptosis in Neurodegeneration

PANoptosis in Neurodegeneration

<div class="infobox infobox-mechanism">

| Property | Value |
|----------|-------|
| Pathway | PANoptosis |
| Full Name | Pyroptosis-Apoptosis-Necroptosis |
| Key Proteins | ZBP1, NLRP3, ASC, CASP1, CASP8, RIPK1, RIPK3, MLKL |
| Cell Death Type | Programmed cell death (hybrid) |
| Discovery | 2016 (Karki et al.) |

</div>

Overview

PANoptosis (Pyroptosis-[Apoptosis](/entities/apoptosis)) is a unique programmed cell death pathway that involves the coordinated activation of pyroptosis, apoptosis, and [necroptosis](/entities/necroptosis)[@karki2021]. Unlike traditional cell death pathways that operate independently, PANoptosis represents an interconnected inflammatory cell death program that cannot be classified into any single cell death category. This hybrid cell death pathway has emerged as a critical mechanism in neurodegenerative diseases, where it contributes to neuronal loss and disease progression[@lee2023].

Molecular Mechanisms

PANoptosome Complex

The PANoptosome is a large multiprotein complex that serves as the central hub for PANoptosis activation[@karki2021]:

```mermaid
flowchart TD
A["ZBP1<br/>Z-DNA Binding Protein 1"] --> B["PANoptosome Complex"]
C["NLRP3"] --> B
D["ASC<br/>PYCARD"] --> B
E["RIPK1"] --> B
F["RIPK3"] --> B

B --> G["Caspace-1"]
B --> H["Caspace-8"]
B --> I["Caspace-3/7"]

G --> J["Pyroptosis<br/>Gasdermin D"]
H --> K["Apoptosis<br/>Caspase-3/7"]
I --> K
B --> L["Necroptosis<br/>ML KL"]

PANoptosis in Neurodegeneration

<div class="infobox infobox-mechanism">

| Property | Value |
|----------|-------|
| Pathway | PANoptosis |
| Full Name | Pyroptosis-Apoptosis-Necroptosis |
| Key Proteins | ZBP1, NLRP3, ASC, CASP1, CASP8, RIPK1, RIPK3, MLKL |
| Cell Death Type | Programmed cell death (hybrid) |
| Discovery | 2016 (Karki et al.) |

</div>

Overview

PANoptosis (Pyroptosis-[Apoptosis](/entities/apoptosis)) is a unique programmed cell death pathway that involves the coordinated activation of pyroptosis, apoptosis, and [necroptosis](/entities/necroptosis)[@karki2021]. Unlike traditional cell death pathways that operate independently, PANoptosis represents an interconnected inflammatory cell death program that cannot be classified into any single cell death category. This hybrid cell death pathway has emerged as a critical mechanism in neurodegenerative diseases, where it contributes to neuronal loss and disease progression[@lee2023].

Molecular Mechanisms

PANoptosome Complex

The PANoptosome is a large multiprotein complex that serves as the central hub for PANoptosis activation[@karki2021]:

Key Molecular Components

Sensors and Initiators

• ZBP1 (Z-DNA binding protein 1): Intracellular Z-nucleic acid sensor that recognizes viral RNA and endogenous retroelements[@rebsamen2021]
• NLRP3 (NLR family pyrin domain containing 3): Inflammasome component that detects cellular stress and damage signals[@liu2020]
• AIM2 (Absent in melanoma 2): DNA sensor that activates inflammasome in response to cytosolic DNA

Adaptor Proteins

• ASC (PYCARD): Adaptor protein linking sensor activation to caspase-1
• FADD: Adaptor for death receptor signaling to caspase-8

Effector Caspases

• Caspase-1: Master regulator of pyroptosis; processes pro-IL-1β, pro-IL-18, and gasdermin D[@liu2020]
• Caspase-8: Key mediator of extrinsic apoptosis and regulator of necroptosis
• Caspase-3/7: Executioner caspases of apoptosis

Necroptosis Effectors

• RIPK1 (Receptor-interacting protein kinase 1): Upstream kinase regulating both apoptosis and necroptosis[@degterev2022]
• RIPK3: Key mediator of necroptosis; phosphorylates MLKL
• MLKL (Mixed lineage kinase domain-like): Executioner of necroptosis; forms pores in plasma membrane

Activation Triggers

PANoptosis can be triggered by multiple stimuli[@lee2023]:

Role in Neurodegenerative Diseases

Alzheimer's Disease

PANoptosis contributes to AD pathogenesis through multiple mechanisms[@song2023]:

• Neuronal loss: PANoptotic cell death drives progressive neuronal demise
• Microglial activation: Inflammasome activation in [microglia](/cell-types/microglia-neuroinflammation) amplifies neuroinflammation
• Amyloid pathology: [Aβ](/proteins/amyloid-beta) aggregates trigger PANoptosome formation
• Tau pathology: NFT formation correlates with PANoptosis markers
• [Blood-brain barrier](/entities/blood-brain-barrier) damage: Endothelial PANoptosis compromises BBB integrity

Parkinson's Disease

In PD, PANoptosis affects dopaminergic [neurons](/entities/neurons)[@gu2023]:

• α-Synuclein toxicity: Pathological α-synuclein activates NLRP3
• Mitochondrial dysfunction: PINK1/Parkin pathway disruption triggers PANoptosis
• Microglial inflammation: Sustained inflammasome activation creates neurotoxic environment
• Dopaminergic neuron loss: PANoptotic cell death contributes to substantia nigra degeneration

Amyotrophic Lateral Sclerosis

PANoptosis mechanisms in ALS[@liu2023]:

• Motor neuron death: PANoptotic pathways mediate motor neuron degeneration
• Glial cell involvement: Astrocyte and microglia PANoptosis contributes to disease
• Protein aggregation: [TDP-43](/mechanisms/tdp-43-proteinopathy) and SOD1 aggregates trigger inflammasome activation
• Excitotoxicity: Glutamate toxicity potentiates PANoptosis signaling

Frontotemporal Dementia

FTD involves PANoptosis through[@huang2023]:

• TDP-43 pathology: Mislocalized TDP-43 activates ZBP1 pathways
• Neuronal vulnerability: Specific neuronal populations show PANoptosis susceptibility
• Inflammatory responses: Chronic neuroinflammation drives PANoptotic cell death

Huntington's Disease

In HD, PANoptosis contributes to[@liu2024]:

• Mutant [huntingtin](/proteins/huntingtin) toxicity: mHTT aggregates activate inflammasome pathways
• Energy dysfunction: Mitochondrial impairment triggers PANoptosis
• Striatal neuron loss: Medium spiny neurons particularly vulnerable

Therapeutic Targeting

Current Pharmacological Approaches

Inflammasome Inhibitors

• MCC950: Potent NLRP3 inhibitor; blocks PANoptosis initiation[@coll2015]
• Dapansutrile (OLT1177): Oral NLRP3 inhibitor in clinical trials
• Dimethyl fumarate: Nrf2 activator with inflammasome-modulating effects

Caspase Inhibitors

• Emricasan: Pan-caspase inhibitor; blocks apoptosis and pyroptosis
• Z-VAD-FMK: Broad-spectrum caspase inhibitor

Kinase Inhibitors

• Necrostatin-1: RIPK1 inhibitor; blocks necroptosis pathway
• GSK'872: RIPK3 inhibitor; prevents MLKL activation
• Sorafenib: Multi-kinase inhibitor with necroptosis-modulating activity

Natural Compounds

• Curcumin: Modulates NLRP3 inflammasome and provides antioxidant effects[@aggarwal2022]
• Resveratrol: SIRT1 activator with anti-PANoptotic properties
• Quercetin: Flavonoid with inflammasome-inhibiting effects
• Sulforaphane: Nrf2 activator; reduces oxidative stress-triggered PANoptosis

Clinical Trials

Several trials are investigating PANoptosis-targeted therapies:

| Compound | Target | Phase | Condition |
|----------|--------|-------|-----------|
| Dapansutrile | NLRP3 | Phase 2 | Osteoarthritis, COVID-19 |
| Dimethyl fumarate | NLRP3/Nrf2 | Phase 3 | MS, ALS |
| Emricasan | Caspases | Phase 2 | Liver disease |

Combination Strategies

• NLRP3 inhibitor + caspase inhibitor: Dual targeting of pyroptosis and apoptosis
• RIPK1 inhibitor + antioxidants: Combined necroptosis blocking and oxidative stress reduction
• Anti-inflammatory + neuroprotective: Addressing both cell death and neuroprotection

Cross-Linking

PANoptosis connects to multiple existing wiki pathways:

• [Pyroptosis](/mechanisms/pyroptosis) - Related cell death pathway
• [Necroptosis in Neurodegeneration](/mechanisms/necroptosis) - Related cell death pathway
• [Apoptosis in Neurodegeneration](/mechanisms/apoptosis-neurodegeneration) - Related cell death pathway
• [NLRP3 Inflammasome in Neurodegeneration](/mechanisms/nlrp3-inflammasome) - Key upstream activator
• [Neuroinflammation](/mechanisms/neuroinflammation) - Inflammatory consequences
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) - Trigger mechanism
• [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathway) - PD trigger
• [Tau Pathology](/mechanisms/tau-pathology) - AD trigger

Research Directions

Biomarkers

• Circulating PANoptosis markers: IL-1β, IL-18, MLKL phosphorylation
• Genetic variants: NLRP3, ZBP1, RIPK1 polymorphisms associated with disease risk

Future Therapies

• Gene therapy: AAV-delivered PANoptosis inhibitors
• Small molecule development: More potent and selective inhibitors
• Cell-permeant peptides: Blocking PANoptosome assembly
• Immunomodulation: Targeting microglial PANoptosis

See Also

• [Pyroptosis](/mechanisms/pyroptosis)
• [Necroptosis in Neurodegeneration](/mechanisms/necroptosis)
• [Apoptosis in Neurodegeneration](/mechanisms/apoptosis-neurodegeneration)
• [NLRP3 Inflammasome in Neurodegeneration](/mechanisms/nlrp3-inflammasome)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathway)
• [Tau Pathology](/mechanisms/tau-pathology)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research (2024-2026)

Recent research on panoptosis in neurodegeneration:

• [Panoptosis: a novel cell death pathway in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/38334678/) (2024)
• [Inflammatory cell death pathways in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/39653749/) (2024)
• [Gasdermin-mediated cell death in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/38878778/) (2024)

References